TBPH EBITDA
Theravance Biopharma Inc · EBITDA
TBPH EBITDA
Latest reported$68.68Mperiod ending
TBPH TTM EBITDA (-$153.63M → $68.68M)
TTM EBITDA
High-resolution chart · PNG
TBPH ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| 68,682,000 | |
| 142,639,000 | |
| 135,831,000 | |
| 53,072,000 | |
| 46,239,000 | |
| -40,332,000 | |
| -36,483,000 | |
| -34,062,000 | |
| -31,184,000 | |
| -33,439,000 | |
| -47,205,000 | |
| -53,702,001 | |
| -59,993,001 | |
| -64,150,001 | |
| -68,366,001 | |
| -92,095,000 | |
| -129,404,000 | |
| -149,374,001 | |
| -204,397,001 | |
| -244,350,001 | |
| -255,108,001 | |
| -266,153,000 | |
| -255,174,000 | |
| -236,229,000 | |
| -230,232,000 | |
| -211,252,000 | |
| -203,601,000 | |
| -195,700,000 | |
| -199,041,000 | |
| -213,500,000 | |
| -212,437,000 | |
| -240,703,000 | |
| -246,289,000 | |
| -264,328,000 | |
| -259,138,000 | |
| -239,762,000 | |
| -209,198,000 | |
| -193,521,000 | |
| -177,748,000 | |
| -175,422,000 | |
| -185,438,000 | |
| -183,093,000 | |
| -179,301,000 | |
| -189,196,000 | |
| -195,808,000 | |
| -207,130,000 | |
| -229,265,000 | |
| -207,679,000 | |
| -199,213,000 | |
| -181,446,000 | |
| -153,631,000 | |
| -138,685,000 | |
| -129,981,000 |